Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use
about
Inhibition of striatal soluble guanylyl cyclase-cGMP signaling reverses basal ganglia dysfunction and akinesia in experimental parkinsonismMechanisms for the modulation of dopamine d(1) receptor signaling in striatal neuronsAnalysis of substrate specificity and kinetics of cyclic nucleotide phosphodiesterases with N'-methylanthraniloyl-substituted purine and pyrimidine 3',5'-cyclic nucleotides by fluorescence spectrometryDistinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatumProtein kinase A phosphorylation of human phosphodiesterase 3B promotes 14-3-3 protein binding and inhibits phosphatase-catalyzed inactivationInactivation of Pde8b enhances memory, motor performance, and protects against age-induced motor coordination decay.Iloprost- and isoproterenol-induced increases in cAMP are regulated by different phosphodiesterases in erythrocytes of both rabbits and humansBinding of cyclic nucleotides to phosphodiesterase 10A and 11A GAF domains does not stimulate catalytic activitycGMP-selective phosphodiesterase inhibitors stimulate mitochondrial biogenesis and promote recovery from acute kidney injuryTreating brain tumors with PDE4 inhibitorsPhosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex.PDE4 inhibitors: current statusDependence of multidrug resistance protein-mediated cyclic nucleotide efflux on the background sodium conductanceSildenafil accelerates reentrainment of circadian rhythms after advancing light schedulesMechanisms of action of glucagon-like peptide 1 in the pancreasNovel Radioligands for Cyclic Nucleotide Phosphodiesterase Imaging with Positron Emission Tomography: An Update on Developments Since 2012Role of Phosphodiesterase 5 and Cyclic GMP in HypertensionPhosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical ImplicationsPharmacological implications of the Ca(2+)/cAMP signaling interaction: from risk for antihypertensive therapy to potential beneficial for neurological and psychiatric disordersTargeting protein-protein interactions in complexes organized by A kinase anchoring proteinsThe ever unfolding story of cAMP signaling in trypanosomatids: vive la difference!Bacillus anthracis edema factor substrate specificity: evidence for new modes of actionTherapeutic potential of PDE modulation in treating heart diseaseExtending the translational potential of targeting NO/cGMP-regulated pathways in the CVSPhosphodiesterases in neurodegenerative disorderscGMP-phosphodiesterase inhibition enhances photic responses and synchronization of the biological circadian clock in rodentsPdeH, a high-affinity cAMP phosphodiesterase, is a key regulator of asexual and pathogenic differentiation in Magnaporthe oryzaeA cyclic GMP signalling module that regulates gliding motility in a malaria parasiteNuclear cGMP-dependent kinase regulates gene expression via activity-dependent recruitment of a conserved histone deacetylase complexPhosphodiesterase inhibition increases CREB phosphorylation and restores orientation selectivity in a model of fetal alcohol spectrum disordersStructural insight into substrate specificity of phosphodiesterase 10The Molecular Basis for Different Recognition of Substrates by Phosphodiesterase Families 4 and 10Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitorsCrystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite-selective inhibitorsConformational Variations of Both Phosphodiesterase-5 and Inhibitors Provide the Structural Basis for the Physiological Effects of Vardenafil and SildenafilAn insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studiesSolution Structure of the cGMP Binding GAF Domain from Phosphodiesterase 5: INSIGHTS INTO NUCLEOTIDE SPECIFICITY, DIMERIZATION, AND cGMP-DEPENDENT CONFORMATIONAL CHANGEThe structure of a complete phytochrome sensory module in the Pr ground stateKinetic and Structural Studies of Phosphodiesterase-8A and Implication on the Inhibitor Selectivity † ‡Insight into Binding of Phosphodiesterase-9A Selective Inhibitors by Crystal Structures and Mutagenesis
P2860
Q21090973-E7BC1C7D-7B83-44C9-AE40-6EE0B156EC54Q21131062-3F3A2187-241C-4ACF-AD88-313169480EDBQ21133756-9275ED32-003E-4B58-AC5F-3FB36BEACA14Q23909635-3C2560BB-A7E3-4086-88B5-38F87E2EBD63Q24294632-0C5D66DF-D0D6-4098-A2D7-02EE4C6A0815Q24297532-8FF8B199-5CEF-44B8-9128-D028E80C3488Q24316393-DA46E17B-BA6E-4D50-A23D-DE465051B2B2Q24336415-7DB56ED4-1AC7-4531-AC5F-995A118EA443Q24596767-CEE9C05C-87F3-4598-B352-632AB3745477Q24628917-487BF319-C1C3-47E3-8701-1470A7963274Q24633622-BC09FE51-3ABA-47BD-84AE-8994F69B9E95Q24651926-F75BA157-3D99-4F69-BEB1-9D54701029F4Q24657005-660908D5-F754-4CD8-8B67-969D591AB54EQ24676329-5978FDC9-39B3-48E6-AD91-84096EEDBBBBQ24683764-AFCC78CC-1A36-4049-B74A-BE00117F61B6Q26746978-38A3AD8D-0242-457C-BBA6-98461BE60C15Q26748049-53D32E91-4186-4172-ABE1-3034FC54CAEDQ26753116-2DE4D458-FC4C-470E-961F-E9E44616655EQ26777845-2FE0A583-13F8-4EDE-9784-556B153ABB26Q26781574-08E0FAC3-3AEB-4FA9-B054-C627785A8A13Q26781588-0A09D7A4-3D73-404A-AF65-BF5ADF04797FQ27000357-635BCD4C-B1D0-423A-9188-378C292E4716Q27005761-5AAAE7A1-FDB0-4E21-A6AC-6F18F53A7AA8Q27021649-A83867ED-0744-4036-BA22-DB2F9AC1FFE9Q27026359-D7183E32-4DE6-46FB-A534-88E6D9C88319Q27302892-C44B8DD4-8EB3-464D-943D-A435D3FA314FQ27314823-A6614187-EDFC-4665-9E7F-1DB0AFD67BEAQ27316208-206991FE-2076-4B9E-8343-606CA9E1CABDQ27340411-2BCBB75A-B39A-4041-B6DB-E6DF044B645EQ27344585-88D18D1D-13A0-4B2F-8B04-ED708FD153B0Q27644254-92624E57-0E31-4052-853E-6E27F61522D0Q27646209-061ACBBA-B159-4D9D-B8DD-D491565A6432Q27647620-D485D410-87B5-40C2-8958-191138233F27Q27648821-80498DA0-B243-497F-AEA2-FDBF7432B94FQ27648887-02383023-82B3-4C79-B164-48E83B17CD2AQ27650091-380B8AB7-6473-4943-BCF7-F8C13F868FDAQ27650760-602D4D45-A740-4054-92A6-57E9C80D55FBQ27652211-29ACB774-BB64-4A09-AD00-7522CF7A5953Q27652751-27A535AE-C733-4A2A-BC71-77B74EFDF403Q27659336-4BC676FE-8DDF-4327-9A8D-8B6DDA8BD168
P2860
Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use
@ast
Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use
@en
Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use
@nl
type
label
Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use
@ast
Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use
@en
Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use
@nl
prefLabel
Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use
@ast
Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use
@en
Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use
@nl
P3181
P356
P1476
Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use
@en
P2093
Andrew T Bender
Joseph A Beavo
P304
P3181
P356
10.1124/PR.58.3.5
P407
P577
2006-09-01T00:00:00Z